JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2022, Vol. 42 ›› Issue (1): 113-118.doi: 10.3969/j.issn.1674-8115.2022.01.017

• Review • Previous Articles    

Research progress of botulinum toxin A in treatment of neurogenic bladder

Lin ZHANG(), Zhong CHEN()   

  1. Department of Urology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
  • Received:2021-07-27 Online:2022-01-28 Published:2022-02-18
  • Contact: Zhong CHEN E-mail:colin201108@163.com;csy2000777@sina.com
  • Supported by:
    Project of Shanghai Municipal Commission of Health and Family Planning(20174011)

Abstract:

In recent years, intradetrusor injection of botulinum toxin A (BTX-A) has achieved satisfactory therapeutic effects on the treatment of neurogenic bladder, improving the bladder function and reducing the lower urinary tract symptoms while improving patients' quality of life. In addition, this therapy has advantages including minimal invasiveness, mild side effects, and allowing repeated injections. At present, there is no international consensus on the injection plan for BTX-A. Therefore, based on the recent clinical research results, this paper reviews the mechanism of action, types, usage, therapeutic effects, influencing factors, as well as adverse reactions and contraindications of BTX-A, in an attempt to provide evidence for its clinical application.

Key words: botulinum toxin A, neurogenic bladder, neurogenic detrusor overactivity

CLC Number: